Clinical trial
Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer…
NCT00044538 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00044538 |
|---|---|
| Title | Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients |
| Official title | An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC) |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | BAY59-8862 (Cytotoxic Taxane) |
| Enrollment | 102 |
| Start date | Dec 1, 2001 |
| Completion | Jun 1, 2004 |
| First posted | Sep 4, 2002 |
| Last update posted | Jun 22, 2009 |
| Countries | Canada, Germany, Israel, Italy, Spain, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: